Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 20 September 1996:
Vol. 273. no. 5282, pp. 1652 - 0
DOI: 10.1126/science.273.5282.1652
Prev | Table of Contents | Next

News & Comment

Eliot Marshall

A 2-year, $1.5 million trial of a once-promising malaria vaccine called SPf66, created by Colombian biochemist Manuel Patarroyo, has found no evidence that the vaccine is effective in preventing or delaying the disease in children. The results, from a U.S. Army-sponsored trial of SPf66 among more than 1200 children in Thailand from 1993 to 1995, indicate that the vaccine "does not protect against clinical falciparum malaria," according to a report published in the 14 September issue of The Lancet. Moreover, the authors write that the data are so disappointing that "further efficacy trials are not warranted."




To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)